In the intricate symphony of human physiology, few instruments play a more pivotal role than the heart. A marvel of ...

此次FDA批准注册标志着公司产品获得进入美国市场销售的资质，这将对产品在海外市场的推广和销售产生积极影响。然而，公告中也提到，产品在相应市场的实际销售情况将受到未来市场推广效果、海外市场政策环境变化以及汇率波动等因素的影响，目前尚无法预测对公司未来经 ...

天眼查资料显示，维力医疗成立于2004年04月30日，注册资本29286.8018万人民币，法定代表人韩广源，注册地址为广州市番禺区化龙镇金湖工业城C区4号。主营业务为麻醉、导尿、泌尿外科、护理、呼吸、 血液透析 ...

在国际医疗市场中，FDA的认可无疑是一种权威背书。这意味着，该产品不仅在质量、安全性上符合严格标准，还具备进入北美市场的资质。获得FDA批准的产品能更容易地被医生推荐，患者使用，从而推动企业的销售增长。这样的认可，为维力医疗的国际化之路铺平了道路。

Coinciding with the FDA’s clearance for the catheter, Perfuze has also completed a €22m ($24m) financing round.

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8523 ...

Basis Medical recently announced that its Seclusion catheter for the treatment of superficial vein reflux has received FDA ...

Olubadewa A. Fatunde and Win-Kuang Shen. Catheter Ablation as the First-Line Therapy for Atrial Fibrillation: Update on Evidence and Clinical Implications. CVIA. 2025. Vol. 10 (1). DOI: ...

VTAK股价已跌至52周新低0.31美元，较52周高点8.40美元下跌96%，公司正在应对充满挑战的市场环境。根据 InvestingPro 分析，尽管目前面临挑战，该公司仍保持着90.5%的高毛利率。这一显著下跌反映了RA Medical ...

Perfuze, a medtech has raised €22m. With the infusion, the company will release its catheters to select stroke centres in the US.

Johnson & Johnson MedTech‘s Shockwave Medical announced the U.S. launch of its Javelin peripheral intravascular lithotripsy ...